SCHEMBL4634717

SCHEMBL4634717

N[C@@H](CO)C(=O)Nc1cc(Cl)ccc1OCC(=O)N1CCC(C(=O)c2ccc(F)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
BLM P54132 1/20 0.47
HSD11B1 P28845 6/20 0.47
MGLL Q99685 2/20 0.47
CCR1 P32246 3/20 0.46
FPR3 P25089 1/20 0.46
GPR65 Q8IYL9 1/20 0.46
GPR35 Q9HC97 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HSD17B10 Q99714 1/20 0.43
UBE2N P61088 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4634607 0.91 CCR1 (0.46) ALDH1A1BLMHSD11B1MGLLCCR1
SCHEMBL4634297 0.89 CCR1 (0.58) ALDH1A1BLMHSD11B1MGLLCCR1
SCHEMBL4634761 0.87 ALDH1A1 (0.43) ALDH1A1BLMHSD11B1MGLLCCR1
SCHEMBL4634367 0.87 CCR1 (0.44) ALDH1A1BLMHSD11B1MGLLCCR1
SCHEMBL4633758 0.87 ALDH1A1 (0.49) ALDH1A1BLMHSD11B1MGLLCCR1
SCHEMBL4634378 0.86 CCR1 (0.42) ALDH1A1BLMHSD11B1MGLLCCR1
SCHEMBL5674687 0.86 CCR1 (0.47) ALDH1A1BLMHSD11B1MGLLCCR1
SCHEMBL4634938 0.85 ALDH1A1 (0.50) ALDH1A1BLMHSD11B1MGLLCCR1
SCHEMBL5671921 0.84 ALDH1A1 (0.47) ALDH1A1BLMHSD11B1MGLLCCR1
SCHEMBL5671959 0.84 ALDH1A1 (0.47) ALDH1A1BLMHSD11B1MGLLCCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928829-A1 PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS Schering Aktiengesellschaft (DE) 2008-06-11 EP claimed
US-20060167044-A1 Piperidine derivatives and their use as anti-inflammatory agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-07-27 US claimed
WO-2006066948-A1 PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2006-06-29 WO claimed
EP-1928829-A1 PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS Schering Aktiengesellschaft (DE) 2008-06-11 EP disclosed
US-20060167044-A1 Piperidine derivatives and their use as anti-inflammatory agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-07-27 US disclosed
WO-2006066948-A1 PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167044-A1 Piperidine derivatives and their use as anti-inflammatory agents CCR1, CCR2, CCR3 ALDH1A1 296/4885BLM 3857/4885HSD11B1 2270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.